Advertisement
Advertisement
Hansoh Pharmaceutical
TOPIC
 / company

Hansoh Pharmaceutical

Hansoh Pharmaceutical
Hansoh Pharmaceutical
Hansoh Pharmaceutical is China's largest maker of psychotropic medication by sales. The company also researches and produces medications in areas of oncology, anti-infections, central nervous system diseases, metabolic diseases and autoimmune diseases. It was founded by Zhong Huijuan, China's third richest woman and wife of Sun Piaoyang, chairman of prominent anti-tumour medication maker Jiangsu Hengrui Medicine.
Chairman / President
Zhong Huijuan
CEO / Managing Director
Zhong Huijuan
CFO / Finance Director
HU Min
Industry
Health & Pharmaceuticals
Website
hspharm.com
Headquarters address
No. 3 Guangming Road, Lianyungang, Jiangsu, China
Stock Code
SEHK:03692
Year founded
1995
LATEST China Science NEWS

How China’s AI carbon accounting model points the finger at the US

videocam
China’s new model distributes responsibility by taking into account who actually consumes exported products and the ability of countries’ natural environments to absorb carbon. Photo: Xinhua

Can Chinese plasma mill give it key tech advantage over US?

9
Some of the equipment used in the plasma mill. Photo: Handout

Chinese scientists replicate eel’s 6,000km breeding journey inside research pool

videocam
5
China accounts for 75 per cent of the world’s farmed eels, stocked with fry sourced from net fishing. Photo: AFP

China achieves a world first, updating stabilisers for renewable energy grids

videocam
The 35kV high-voltage direct-connection synchronous condenser developed by Chinese researchers. Photo: Handout

Semiconductors | China bets on RISC-V in global AI race

China bets on RISC-V in global AI race
MORE China Science NEWS
A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
Illustration: Lau Ka-kuen
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Advertisement
Advertisement
Advertisement
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Hong Kong stock market

Hong Kong stock rally extends as investors bet on US-China trade agreement

Investors shrug off US President Donald Trump’s mention of a 155 per cent tariff on Chinese goods if negotiations fail.

Hong Kong stock market

Hong Kong stocks surge on trade optimism, China economic growth

Benchmark rebounds from last week’s loss after ‘constructive’ talk between US treasury secretary, Chinese vice-premier.

A worker looks on near a cargo ship carrying containers at the Yantian port in Shenzhen, Guangdong province on May 9, 2025. Photo: Reuters
Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

China’s Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Banking & finance

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

Investor focus was on companies that address cardiovascular, cancer and other life-threatening conditions. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

People walk past an electronic board showing the Hang Seng Index in Hong Kong. Photo: Zuma Press Wire/dpa
Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Hong Kong stock market

Rally in solar and EV stocks lifts Hong Kong benchmark to 3½-year high

Expectations are high that the July Politburo meeting will introduce more measures to eliminate excess capacity in some emerging industries.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Mainland investors on track to beat Hong Kong stock buying record set in 2024

Investors from the mainland buy more than US$93 billion worth of Hong Kong stocks in the first half of 2025.

Exchange Square in Central. Photo: Eugene Lee
Hong Kong stock market

Hong Kong stocks drop as PDD’s profit slump rattles Alibaba, e-commerce peers

PDD’s overnight slump in New York infected e-commerce stocks amid concerns price discounting will erode margins.

videocam
Science

The Chinese chemists turning science into fortunes

Chinese chemistry professor Fan Daidi has synthesised collagen into a commercial success.

videocam
Hong Kong stock market

Hong Kong stocks rise even as looming Trump tariffs keep sentiment in check

The Hang Seng Index is under consolidation as traders await development on the US tariffs front, says analyst Kenny Wen.

Hang Seng Index data is displayed at the Hong Kong stock exchange. Photo: Nora Tam
Hong Kong stock market

Hang Seng review shines light on China’s 6th richest woman at Hansoh Pharma

Hansoh Pharmaceutical, founded by China’s sixth richest woman, rose with two other new members, before officially joining the benchmark index on September 5. Chow Tai Fook Jewellery surrendered gain.

videocam
Hansoh Pharmaceutical headquarters in Shanghai. Photo: Company website
Millionaires and billionaires

How chemistry teacher Zhong Huijuan became the world’s richest self-made woman

She’s been playfully compared to Breaking Bad’s Walter White for her career change – now the Hansoh Pharmaceutical founder is 2020’s richest self-made billionaire

Stocks

Chem teacher behind pharmaceutical firm to be China’s third-richest woman

Zhong Huijuan will have US$7.9 billion fortune after her Hansoh Pharmaceutical Group goes public in Hong Kong on Friday

A technician loads containers on a rack at a Cyagen Biosciences facility in Jiangsu province, China, in March. Photo: Bloomberg
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement